admin A new yogurt drink is hitting shelves this month with a very specific goal, helping GLP-1 medication users maintain muscle mass while losing weight. The launch, called Oikos Fusion, targets consumers taking drugs such as Ozempic, which can lead to significant muscle loss alongside fat reduction.
Data shows that nearly 10% of the U.S. population has tried or currently uses GLP-1 treatments. According to health experts, about 20% of weight lost through these medications comes from muscle. This poses long-term health concerns for patients. Oikos Fusion has been developed to address that problem directly.
Each 7-ounce bottle contains 23 grams of complete protein, 5 grams of prebiotic fiber, and a patented blend of whey, leucine, and vitamin D. The formulation supports muscle synthesis, the body’s process of building and repairing muscle, while also aiding digestive health. Vitamins B3 and B12 are included to help convert food into energy.
The company began developing Oikos Fusion a year ago, drawing on research from its specialized nutrition division. This allowed it to speed up the launch and save costs. The formula uses 2 to 3 grams of leucine, paired with adequate protein and vitamin D, to trigger muscle-building processes effectively.
Although designed with GLP-1 users in mind, the drink also appeals to active consumers looking to maintain muscle. Appetite suppression from GLP-1 use has led many people to seek smaller, nutrient-dense foods, creating new opportunities in the yogurt category.
Oikos Fusion will debut in Walmart stores nationwide this month, with a broader rollout to Target, Kroger, and Wakefern in October. Flavors include strawberry, mixed berry, and vanilla.
The launch comes after a strong year for the Oikos brand, which saw a 40% jump in retail sales in 2024, surpassing $1 billion for the first time. It follows the company’s recent entry into the $7 billion protein shake market with a shelf-stable, on-the-go offering.
By combining high protein content, gut health benefits, and a targeted muscle-retention formula, Oikos Fusion aims to meet the needs of both GLP-1 medication users and the broader health-conscious market. The product positions the brand at the center of two fast-growing nutrition trends, functional foods and personalized health solutions.
Magazine 
